Fate Therapeutics (FATE) Misses Q1 EPS by 1c

Fate Therapeutics (NASDAQ: FATE) reported Q1 EPS of ($0.34), $0.01 worse than the analyst estimate of ($0.33).

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• AXT appoints Tracy Liu to its board of directors
• MP Materials seen largely insulated after China export-control move